Shunsuke Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shunsuke Yamamoto has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Shouichi Ohga
Department of Pediatrics. Graduate School of Medical Sciences Kyushu University Fukuoka Japan
5 shared publicationsYuhki Koga
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Perinatal and Pediatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
4 shared publicationsUtako Oba
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
3 shared publications- Yuhki Koga
Department of Pediatrics National Hospital Organization Kyushu Cancer Center Fukuoka Japan
3 shared publications - Daisuke Ishihara
Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan
2 shared publications Hiroaki Ono
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Society of Hematology in Blood Advances
Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12
Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL). Although recent reports describe some improvement, survival in DS-ALL remains inferior to that of non-DS-ALL. This study evaluated the prognosis, relapse patterns, and treatment-related toxicities of DS-ALL in the Japan Children's Cancer Group ALL-B12 trial, a nationwide prospective study using risk-adapted therapy. A total of 1,804 patients, including 44 DS-ALL, were analyzed. Risk classification used standardized criteria. The 5-year event-free survival and overall survival in DS-ALL were 70.5% and 81.8%, respectively, lower than 85.6% and 94.6% in non-DS-ALL (P < 0.001). Survival differences were most pronounced in standard-risk patients. DS-ALL showed fewer favorable genetics and relapse patterns dominated by isolated bone marrow events, with no CNS relapse. CRLF2 rearrangement was assessable in 43 of 44 DS-ALL cases; 15 of 43 (34.9%) were positive. In an exploratory analysis excluding canonical favorable or unfavorable subtypes (n = 36), the 5-year EFS in DS-ALL with and without CRLF2 rearrangement were 57.1% and 81.8%, respectively (P = 0.300), and the corresponding 5-year OS were 78.6% and 86.4%, respectively (P = 0.331). Treatment-related toxicities were more frequent in DS-ALL, including mucositis (27.3% vs. 7.1%), hyperglycemia (25.0% vs. 6.9%), and pulmonary infections (20.5% vs. 7.4%). Among DS-ALL patients with TP2 MRD ≥ 10-4 (n = 3), all relapsed and died within three years. No treatment-related death was recorded after induction, but one death of undetermined cause occurred. These findings highlight the continuing need to optimize DS-ALL therapy to reduce relapse and toxicity. UMIN CT Registry (UMIN000009339) and JCT (jRCTs041180101).
- 15 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessPrognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12
Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL). Although recent reports describe some improvement, survival in DS-ALL remains inferior to that of non-DS-ALL. This study evaluated the prognosis, relapse patterns, and treatment-related toxicities of DS-ALL in the Japan Children's Cancer Group ALL-B12 trial, a nationwide prospective study using risk-adapted therapy. A total of 1,804 patients, including 44 DS-ALL, were analyzed. Risk classification used standardized criteria. The 5-year event-free survival and overall survival in DS-ALL were 70.5% and 81.8%, respectively, lower than 85.6% and 94.6% in non-DS-ALL (P < 0.001). Survival differences were most pronounced in standard-risk patients. DS-ALL showed fewer favorable genetics and relapse patterns dominated by isolated bone marrow events, with no CNS relapse. CRLF2 rearrangement was assessable in 43 of 44 DS-ALL cases; 15 of 43 (34.9%) were positive. In an exploratory analysis excluding canonical favorable or unfavorable subtypes (n = 36), the 5-year EFS in DS-ALL with and without CRLF2 rearrangement were 57.1% and 81.8%, respectively (P = 0.300), and the corresponding 5-year OS were 78.6% and 86.4%, respectively (P = 0.331). Treatment-related toxicities were more frequent in DS-ALL, including mucositis (27.3% vs. 7.1%), hyperglycemia (25.0% vs. 6.9%), and pulmonary infections (20.5% vs. 7.4%). Among DS-ALL patients with TP2 MRD ≥ 10-4 (n = 3), all relapsed and died within three years. No treatment-related death was recorded after induction, but one death of undetermined cause occurred. These findings highlight the continuing need to optimize DS-ALL therapy to reduce relapse and toxicity. UMIN CT Registry (UMIN000009339) and JCT (jRCTs041180101).
- Open Access
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 768-782
Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells
Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming to bypass OXPHOS inhibition. This metabolic shift is supported by enhanced ribosome biogenesis, which is sustained by upregulated de novo guanine nucleotide biosynthesis. Abundant guanine nucleotides suppress the impaired ribosome biogenesis checkpoint (IRBC), leading to TP53 destabilization and persistent MYC expression. The inhibition of inosine monophosphate dehydrogenases (IMPDH1/2) depletes guanine nucleotides, activates IRBC, stabilizes TP53, represses MYC, and impairs the metabolic shift to glycolysis. This metabolic rewiring disrupts LSC stemness and suppresses the reconstitution of human AML cells in xenotransplantation experiments. Notably, the suppression of LSC stemness was observed regardless of Ven resistance or the TP53 mutational status of AML cells. These findings reveal that mutation-independent TP53 inactivation is involved in resistant AML and suggest that targeting guanine nucleotide biosynthesis may offer a clinically actionable strategy to eradicate therapy-resistant LSC.
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 768-782
Open AccessGuanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells
Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming to bypass OXPHOS inhibition. This metabolic shift is supported by enhanced ribosome biogenesis, which is sustained by upregulated de novo guanine nucleotide biosynthesis. Abundant guanine nucleotides suppress the impaired ribosome biogenesis checkpoint (IRBC), leading to TP53 destabilization and persistent MYC expression. The inhibition of inosine monophosphate dehydrogenases (IMPDH1/2) depletes guanine nucleotides, activates IRBC, stabilizes TP53, represses MYC, and impairs the metabolic shift to glycolysis. This metabolic rewiring disrupts LSC stemness and suppresses the reconstitution of human AML cells in xenotransplantation experiments. Notably, the suppression of LSC stemness was observed regardless of Ven resistance or the TP53 mutational status of AML cells. These findings reveal that mutation-independent TP53 inactivation is involved in resistant AML and suggest that targeting guanine nucleotide biosynthesis may offer a clinically actionable strategy to eradicate therapy-resistant LSC.
- 6 January 2025
- Published by Elsevier in Early Human Development
- Vol. 201, 106195
Parental occupational exposure to anticancer drugs and radiation: Risk of fetal loss and physical abnormalities in The Japan Environment and Children's Study
- 6 January 2025
- Published by Elsevier in Early Human Development
- Vol. 201, 106195
Parental occupational exposure to anticancer drugs and radiation: Risk of fetal loss and physical abnormalities in The Japan Environment and Children's Study
- Open Access
- 6 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (3) , e31510
Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan
Programs allowing access to investigational drugs and off‐label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese “Patient‐Proposed Healthcare Services” evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off‐label medications to four enrolled patients, two with low‐grade glioma and two with high‐grade glioma (median age: 10.5 years), until regulatory approval. The timeframe and data collection from such access programs need to be optimized for pediatric patients in accordance with the healthcare system of each nation.
- 6 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (3) , e31510
Open AccessAccess Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan
Programs allowing access to investigational drugs and off‐label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese “Patient‐Proposed Healthcare Services” evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off‐label medications to four enrolled patients, two with low‐grade glioma and two with high‐grade glioma (median age: 10.5 years), until regulatory approval. The timeframe and data collection from such access programs need to be optimized for pediatric patients in accordance with the healthcare system of each nation.
- Open Access
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31331
Early defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood
Background: Veno‐occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life‐threatening complications of hematopoietic cell transplantation (HCT). Methods: We studied the impact of early defibrotide (DF) therapy on the outcomes of pediatric patients with VOD/SOS after transplantation, focusing on recent immunotherapies. A total of 111 pediatric patients who underwent HCT for malignant disease between February 2017 and March 2023 at Kyushu University Hospital were included. Results: Among 111 patients of less than 20 years of age who underwent HCT for malignancy at a single institution between 2017 and 2023, VOD/SOS occurred in 25 (23%) patients. VOD/SOS developed more frequently in the post‐DF era (2020–2023, n = 58) than in the pre‐DF era (31% vs. 13%, p = .04). The proportion of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) was higher in the post‐DF era than in the pre‐DF era (44% vs. 8%, p = .04). Early DF therapy that was started at two European Society for Blood and Marrow Transplantation diagnostic criteria reduced the severity of VOD/SOS ( p < .01) in comparison to non‐early therapy started at less than two criteria. A multivariate analysis indicated that a history of cytokine release syndrome (odds ratio [OR] = 10.4, p = .01) and juvenile myelomonocytic leukemia (OR = 8.98, p = .04), but not an endothelial activation and stress index (EASIX) score of greater than 0.85, were independent risk factors for VOD/SOS. Conclusions: Early DF therapy improves the severity and survival outcomes of post‐transplant VOD/SOS in children. However, its incidence is increasing in the era of immunotherapy for progressive diseases.
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31331
Open AccessEarly defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood
Background: Veno‐occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life‐threatening complications of hematopoietic cell transplantation (HCT). Methods: We studied the impact of early defibrotide (DF) therapy on the outcomes of pediatric patients with VOD/SOS after transplantation, focusing on recent immunotherapies. A total of 111 pediatric patients who underwent HCT for malignant disease between February 2017 and March 2023 at Kyushu University Hospital were included. Results: Among 111 patients of less than 20 years of age who underwent HCT for malignancy at a single institution between 2017 and 2023, VOD/SOS occurred in 25 (23%) patients. VOD/SOS developed more frequently in the post‐DF era (2020–2023, n = 58) than in the pre‐DF era (31% vs. 13%, p = .04). The proportion of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) was higher in the post‐DF era than in the pre‐DF era (44% vs. 8%, p = .04). Early DF therapy that was started at two European Society for Blood and Marrow Transplantation diagnostic criteria reduced the severity of VOD/SOS ( p < .01) in comparison to non‐early therapy started at less than two criteria. A multivariate analysis indicated that a history of cytokine release syndrome (odds ratio [OR] = 10.4, p = .01) and juvenile myelomonocytic leukemia (OR = 8.98, p = .04), but not an endothelial activation and stress index (EASIX) score of greater than 0.85, were independent risk factors for VOD/SOS. Conclusions: Early DF therapy improves the severity and survival outcomes of post‐transplant VOD/SOS in children. However, its incidence is increasing in the era of immunotherapy for progressive diseases.
- Open Access
- 2 February 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (3) , 785-796
Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug–induced thromboembolism
Immunomodulatory drugs (IMiDs) are key drugs for treating multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the interaction between cell-specific substrates and cereblon, a substrate receptor of the E3 ubiquitin ligase complex. Thus, identification of cell-specific substrates is important for understanding the effects of IMiDs. IMiDs increase the risk of thromboembolism, which sometimes results in fatal clinical outcomes. In this study, we sought to clarify the molecular mechanisms underlying IMiDs-induced thrombosis. We investigated cereblon substrates in human megakaryocytes using liquid chromatography–mass spectrometry and found that thrombospondin-1 (THBS-1), which is an inhibitor of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, functions as an endogenous substrate in human megakaryocytes. IMiDs inhibited the proteasomal degradation of THBS-1 by impairing the recruitment of cereblon to THBS-1, leading to aberrant accumulation of THBS-1. We observed a significant increase in THBS-1 in peripheral blood mononuclear cells as well as larger von Willebrand factor multimers in the plasma of patients with myeloma, who were treated with IMiDs. These results collectively suggest that THBS-1 represents an endogenous substrate of cereblon. This pairing is disrupted by IMiDs, and the aberrant accumulation of THBS-1 plays an important role in the pathogenesis of IMiDs-induced thromboembolism.
- 2 February 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (3) , 785-796
Open AccessThrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug–induced thromboembolism
Immunomodulatory drugs (IMiDs) are key drugs for treating multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the interaction between cell-specific substrates and cereblon, a substrate receptor of the E3 ubiquitin ligase complex. Thus, identification of cell-specific substrates is important for understanding the effects of IMiDs. IMiDs increase the risk of thromboembolism, which sometimes results in fatal clinical outcomes. In this study, we sought to clarify the molecular mechanisms underlying IMiDs-induced thrombosis. We investigated cereblon substrates in human megakaryocytes using liquid chromatography–mass spectrometry and found that thrombospondin-1 (THBS-1), which is an inhibitor of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, functions as an endogenous substrate in human megakaryocytes. IMiDs inhibited the proteasomal degradation of THBS-1 by impairing the recruitment of cereblon to THBS-1, leading to aberrant accumulation of THBS-1. We observed a significant increase in THBS-1 in peripheral blood mononuclear cells as well as larger von Willebrand factor multimers in the plasma of patients with myeloma, who were treated with IMiDs. These results collectively suggest that THBS-1 represents an endogenous substrate of cereblon. This pairing is disrupted by IMiDs, and the aberrant accumulation of THBS-1 plays an important role in the pathogenesis of IMiDs-induced thromboembolism.
- 25 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (4) , 311-319
Pediatric leukemia and maternal occupational exposure to anticancer drugs: the Japan Environment and Children’s Study
Occupational exposure to medical agents and ionizing radiation has been suggested as a possible risk factor for childhood cancer. However, the relationship between such exposure and pediatric malignant neoplasms has not yet been comprehensively studied. This cohort study aimed to investigate the association between parental occupational exposure to hazardous medical agents or ionizing radiation and the risk of childhood cancer in offspring. Data from a large birth cohort in Japan, which included 104 062 fetuses, were analyzed. The primary outcome was the development of leukemia or brain tumors diagnosed by community physicians during the first 3 years after birth. Exposure factors were medical agents, including anticancer agents, ionizing radiation, and anesthetics, handled by mothers during pregnancy or by fathers for 3 months before conception. The incidence of leukemia, but not of brain tumors, was higher in mothers exposed to anticancer drugs. Multivariable regression analysis showed that maternal exposure to anticancer drugs was associated with an increased risk of leukemia in offspring older than 1 year (adjusted relative risk, 7.99 [95% confidence interval, 1.98-32.3]). Detailed information obtained from medical certificates of patients with identified leukemia revealed no infant leukemia but acute lymphoblastic leukemias in the exposed group. Our findings suggest that maternal occupational exposure to anticancer drugs may be a potential risk factor for acute lymphoblastic leukemia in offspring older than 1 year. Effective prevention methods may be necessary to prevent maternal exposure to anticancer drugs and to reduce the risk of childhood malignant neoplasms.
- 25 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (4) , 311-319
Pediatric leukemia and maternal occupational exposure to anticancer drugs: the Japan Environment and Children’s Study
Occupational exposure to medical agents and ionizing radiation has been suggested as a possible risk factor for childhood cancer. However, the relationship between such exposure and pediatric malignant neoplasms has not yet been comprehensively studied. This cohort study aimed to investigate the association between parental occupational exposure to hazardous medical agents or ionizing radiation and the risk of childhood cancer in offspring. Data from a large birth cohort in Japan, which included 104 062 fetuses, were analyzed. The primary outcome was the development of leukemia or brain tumors diagnosed by community physicians during the first 3 years after birth. Exposure factors were medical agents, including anticancer agents, ionizing radiation, and anesthetics, handled by mothers during pregnancy or by fathers for 3 months before conception. The incidence of leukemia, but not of brain tumors, was higher in mothers exposed to anticancer drugs. Multivariable regression analysis showed that maternal exposure to anticancer drugs was associated with an increased risk of leukemia in offspring older than 1 year (adjusted relative risk, 7.99 [95% confidence interval, 1.98-32.3]). Detailed information obtained from medical certificates of patients with identified leukemia revealed no infant leukemia but acute lymphoblastic leukemias in the exposed group. Our findings suggest that maternal occupational exposure to anticancer drugs may be a potential risk factor for acute lymphoblastic leukemia in offspring older than 1 year. Effective prevention methods may be necessary to prevent maternal exposure to anticancer drugs and to reduce the risk of childhood malignant neoplasms.
- 23 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (2) , e29915
A preterm newborn‐onset juvenile myelomonocytic leukemia‐like myeloproliferation with PTPN11 mutation
- 23 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (2) , e29915
A preterm newborn‐onset juvenile myelomonocytic leukemia‐like myeloproliferation with PTPN11 mutation
- Open Access
- 25 July 2022
- Published by American Physical Society (APS) in Physical Review B
- Vol. 106 (4) , 045136
Collective mode excitations and simulated -edge resonant inelastic x-ray scattering spectra in antiferromagneticUsing the three-orbital Hubbard model, we investigate the low-energy excitation spectra in the antiferromagnetic phase of . We calculate the dynamical susceptibilities in the low-energy region by the random phase approximation and find that the anisotropic dispersion of the transverse mode is in good agreement with the spectra recently reported by inelastic neutron scattering experiments. By the fast-collision approximation, we simulate the resonant inelastic x-ray scattering (RIXS) spectra of the Ru edge from the dynamical susceptibilities. We show that the dispersion of the transverse mode is clearly observed in the calculated RIXS spectra and that the polarization dependence of the incident x rays enables one to distinguish between the excitations of the in-plane transverse mode and out-of-plane transverse mode.- 25 July 2022
- Published by American Physical Society (APS) in Physical Review B
- Vol. 106 (4) , 045136
Open AccessCollective mode excitations and simulated -edge resonant inelastic x-ray scattering spectra in antiferromagneticUsing the three-orbital Hubbard model, we investigate the low-energy excitation spectra in the antiferromagnetic phase of . We calculate the dynamical susceptibilities in the low-energy region by the random phase approximation and find that the anisotropic dispersion of the transverse mode is in good agreement with the spectra recently reported by inelastic neutron scattering experiments. By the fast-collision approximation, we simulate the resonant inelastic x-ray scattering (RIXS) spectra of the Ru edge from the dynamical susceptibilities. We show that the dispersion of the transverse mode is clearly observed in the calculated RIXS spectra and that the polarization dependence of the incident x rays enables one to distinguish between the excitations of the in-plane transverse mode and out-of-plane transverse mode. - Open Access
- 1 April 2022
- Published by Japan Institute of Metals in MATERIALS TRANSACTIONS
- Vol. 63 (4) , 612-621
In-Situ Observation of Initial Stage Cosmetic Corrosion Behavior under Wet and Dry Conditions
It is well known that the types of automotive corrosion can be divided into perforation corrosion and cosmetic corrosion. Although the mechanism of perforation corrosion has been studied extensively, the mechanism of cosmetic corrosion has not yet been clarified. The authors investigated the cosmetic corrosion behavior of cold-rolled steel sheets without galvanizing with an in-situ observation device. After coating the samples by cathodic electrodeposition (ED), the sample surface was scribed with a cutter. Corrosion resistance was evaluated under cyclic corrosion test. It was found that the progress of under-film corrosion consisted of 3 steps. The 1st step occurs in the initial stage of the dry process in the 1st cycle. In this step, red rust gradually changed to black rust. The 2nd step occurs in the latter stage of the dry process, and under-film corrosion progressed from the scribed part. The 3rd step occurs in the wet process, and in this step, the tip of the under-film corrosion displayed swelling behavior. In the 2nd cycle, the 2nd step and 3rd step of the 1st cycle were repeated. Under-film corrosion progressed at almost the same rate as in the 1st cycle. This Paper was Originally Published in Japanese in Zairyo-to-Kankyo 69 (2020) 212–220.
- 1 April 2022
- Published by Japan Institute of Metals in MATERIALS TRANSACTIONS
- Vol. 63 (4) , 612-621
Open AccessIn-Situ Observation of Initial Stage Cosmetic Corrosion Behavior under Wet and Dry Conditions
It is well known that the types of automotive corrosion can be divided into perforation corrosion and cosmetic corrosion. Although the mechanism of perforation corrosion has been studied extensively, the mechanism of cosmetic corrosion has not yet been clarified. The authors investigated the cosmetic corrosion behavior of cold-rolled steel sheets without galvanizing with an in-situ observation device. After coating the samples by cathodic electrodeposition (ED), the sample surface was scribed with a cutter. Corrosion resistance was evaluated under cyclic corrosion test. It was found that the progress of under-film corrosion consisted of 3 steps. The 1st step occurs in the initial stage of the dry process in the 1st cycle. In this step, red rust gradually changed to black rust. The 2nd step occurs in the latter stage of the dry process, and under-film corrosion progressed from the scribed part. The 3rd step occurs in the wet process, and in this step, the tip of the under-film corrosion displayed swelling behavior. In the 2nd cycle, the 2nd step and 3rd step of the 1st cycle were repeated. Under-film corrosion progressed at almost the same rate as in the 1st cycle. This Paper was Originally Published in Japanese in Zairyo-to-Kankyo 69 (2020) 212–220.